用于阿尔茨海默病的临床抗糖尿病药物：从基础发现到治疗药物开发。
Clinical antidiabetic medication used in Alzheimer's disease: From basic discovery to therapeutics development.
作者信息
Huang Juan, Huang Nanqu, Cui Di, Shi Jingshan, Qiu Yu
机构信息
Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China.
出版信息
Front Aging Neurosci. 2023 Feb 10;15:1122300. doi: 10.3389/fnagi.2023.1122300. eCollection 2023.
Abstract
Alzheimer's disease (AD) is a common neurodegenerative disease. Type 2 diabetes mellitus (T2DM) appears to increase and contributing to the risk of AD. Therefore, there is increasing concern about clinical antidiabetic medication used in AD. Most of them show some potential in basic research, but not in clinical research. So we reviewed the opportunities and challenges faced by some antidiabetic medication used in AD from basic to clinical research. Based on existing research progress, this is still the hope of some patients with special types of AD caused by rising blood glucose or/and insulin resistance.
摘要
阿尔茨海默病（AD）是一种常见的神经退行性疾病。2型糖尿病（T2DM）似乎会增加患AD的风险并促使其发病。因此，人们越来越关注用于AD治疗的临床抗糖尿病药物。它们中的大多数在基础研究中显示出一定潜力，但在临床研究中却并非如此。所以我们回顾了一些用于AD治疗的抗糖尿病药物从基础研究到临床研究所面临的机遇与挑战。基于现有的研究进展，这对于一些由血糖升高和/或胰岛素抵抗引起的特殊类型AD患者来说仍抱有希望。
相似文献
1
Clinical antidiabetic medication used in Alzheimer's disease: From basic discovery to therapeutics development.用于阿尔茨海默病的临床抗糖尿病药物：从基础发现到治疗药物开发。
Front Aging Neurosci. 2023 Feb 10;15:1122300. doi: 10.3389/fnagi.2023.1122300. eCollection 2023.
2
Global View on Alzheimer's Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer's Disease and Diabetes Mellitus.全球视角下的阿尔茨海默病与糖尿病：威胁、风险与治疗——阿尔茨海默病与糖尿病。
Curr Alzheimer Res. 2018;15(14):1277-1282. doi: 10.2174/1567205015666180925110222.
3
Natural bioactive compounds in Alzheimer's disease: From the perspective of type 3 diabetes mellitus.阿尔茨海默病中的天然生物活性化合物：从3型糖尿病的角度来看
Front Aging Neurosci. 2023 Mar 16;15:1130253. doi: 10.3389/fnagi.2023.1130253. eCollection 2023.
4
Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.用于阿尔茨海默病和帕金森病的抗糖尿病药物：重新利用胰岛素、二甲双胍和噻唑烷二酮。
Int Rev Neurobiol. 2020;155:37-64. doi: 10.1016/bs.irn.2020.02.010. Epub 2020 Aug 11.
5
A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.两种疾病的故事：探索将糖尿病与阿尔茨海默病联系起来的机制
J Alzheimers Dis. 2022;85(2):485-501. doi: 10.3233/JAD-210612.
6
Alzheimer's disease and type 2 diabetes mellitus: similarities in pathomechanisms lead to therapeutic opportunities.阿尔茨海默病与 2 型糖尿病：发病机制的相似性带来治疗机会。
Neurol Neurochir Pol. 2021;55(5):418-428. doi: 10.5603/PJNNS.a2021.0056. Epub 2021 Aug 6.
7
Diabetic Theory in Anti-Alzheimer's Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents.抗阿尔茨海默病药物研发中的糖尿病理论——第 1 部分：抗糖尿病药物的治疗潜力。
Curr Med Chem. 2020;27(39):6658-6681. doi: 10.2174/0929867326666191011144818.
8
Alzheimer's disease and type 2 diabetes mellitus: A systematic review of proteomic studies.阿尔茨海默病与 2 型糖尿病：蛋白质组学研究的系统综述。
J Neurochem. 2021 Mar;156(6):753-776. doi: 10.1111/jnc.15166. Epub 2020 Oct 7.
9
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?糖尿病和阿尔茨海默病：共同的发病机制和治疗方法？
Br J Clin Pharmacol. 2011 Mar;71(3):365-76. doi: 10.1111/j.1365-2125.2010.03830.x.
10
Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer's Disease.使用抗糖尿病药物胰高血糖素样肽1受体激动剂治疗阿尔茨海默病的新证据。
touchREV Endocrinol. 2023 May;19(1):16-24. doi: 10.17925/EE.2023.19.1.16. Epub 2023 May 23.
引用本文的文献
1
The multifaceted roles of apolipoprotein E4 in Alzheimer's disease pathology and potential therapeutic strategies.载脂蛋白E4在阿尔茨海默病病理中的多方面作用及潜在治疗策略。
Cell Death Discov. 2025 Jul 8;11(1):312. doi: 10.1038/s41420-025-02600-y.
2
Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials.抗糖尿病药物在阿尔茨海默病中的疗效和安全性比较：一项随机对照试验的网状Meta分析
J Prev Alzheimers Dis. 2025 May;12(5):100111. doi: 10.1016/j.tjpad.2025.100111. Epub 2025 Feb 28.
3
The role of AMPKα subunit in Alzheimer's disease: In-depth analysis and future prospects.AMPKα亚基在阿尔茨海默病中的作用：深入分析与未来展望。
Heliyon. 2024 Jul 6;10(13):e34254. doi: 10.1016/j.heliyon.2024.e34254. eCollection 2024 Jul 15.
4
Novel targets and therapies of metformin in dementia: old drug, new insights.二甲双胍在痴呆症中的新靶点与新疗法：老药新认识
Front Pharmacol. 2024 May 31;15:1415740. doi: 10.3389/fphar.2024.1415740. eCollection 2024.
5
Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review.探索抗糖尿病药物作为阿尔茨海默病和帕金森病治疗方法的潜力：一项综述。
Cureus. 2023 Sep 6;15(9):e44763. doi: 10.7759/cureus.44763. eCollection 2023 Sep.
本文引用的文献
1
Lecanemab for Alzheimer's disease: tempering hype and hope.用于治疗阿尔茨海默病的lecanemab：缓和炒作与希望。
Lancet. 2022 Dec 3;400(10367):1899. doi: 10.1016/S0140-6736(22)02480-1.
2
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study.评估二甲双胍靶点降低普通人群阿尔茨海默病风险的疗效和机制：一项孟德尔随机研究。
Diabetologia. 2022 Oct;65(10):1664-1675. doi: 10.1007/s00125-022-05743-0. Epub 2022 Jul 29.
3
Association Between Metformin and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Clinical Observational Studies.二甲双胍与阿尔茨海默病的关联：临床观察性研究的系统评价和荟萃分析。
J Alzheimers Dis. 2022;88(4):1311-1323. doi: 10.3233/JAD-220180.
4
Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study.在阿尔茨海默病早期接受二甲双胍治疗的糖尿病患者表现出更好的综合表现：来自 ADNI 研究的数据。
Geroscience. 2022 Jun;44(3):1791-1805. doi: 10.1007/s11357-022-00568-6. Epub 2022 Apr 20.
5
Association Between Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Cognitive Function in a Longitudinal Study of Patients with Type 2 Diabetes.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的使用与 2 型糖尿病患者纵向研究中的认知功能的关系。
J Alzheimers Dis. 2022;87(2):635-642. doi: 10.3233/JAD-215678.
6
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.恩格列净可改善伴有射血分数保留的心力衰竭的 2 型糖尿病虚弱老年患者的认知障碍。
Diabetes Care. 2022 May 1;45(5):1247-1251. doi: 10.2337/dc21-2434.
7
Low-dose metformin targets the lysosomal AMPK pathway through PEN2.低剂量二甲双胍通过 PEN2 靶向溶酶体 AMPK 通路。
Nature. 2022 Mar;603(7899):159-165. doi: 10.1038/s41586-022-04431-8. Epub 2022 Feb 23.
8
New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs.阿尔茨海默病的新治疗方法：以抗糖尿病药物为中心的临床前研究和临床试验。
Expert Opin Investig Drugs. 2022 Jan;31(1):105-123. doi: 10.1080/13543784.2022.2022122. Epub 2022 Jan 2.
9
Association of metformin use with Alzheimer's disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study.二甲双胍的使用与新诊断为 2 型糖尿病患者的阿尔茨海默病之间的关联：基于人群的巢式病例对照研究。
Sci Rep. 2021 Dec 15;11(1):24069. doi: 10.1038/s41598-021-03406-5.
10
Altered Hippocampal Subfields Volumes Is Associated With Memory Function in Type 2 Diabetes Mellitus.海马亚区体积改变与2型糖尿病的记忆功能相关。
Front Neurol. 2021 Nov 25;12:756500. doi: 10.3389/fneur.2021.756500. eCollection 2021.
Zotero 插件